Skip to main content
. 2023 Feb 16;13:2811. doi: 10.1038/s41598-023-28773-z

Figure 5.

Figure 5

Inhibitory effect of 1′-O-methyl-averantin on Gli-overexpression models. (A) Gli-luc reporter assays: NIH 3T3 cells stably incorporating Gli-dependent firefly luciferase and constitutive Renilla luciferase reporters were treated with 2.5, 5 or 10 μg/mL crude extract, 1′-O-methyl-averantin, 5 μg/mL GANT61 (a Gli inhibitor), and Vismodegib-GDC-0449 (a SMO inhibitor) and incubated 48 h. (B) Gli-luc reporter assays in HEK293T. HEK293T cells transfected with si-negative control and/or si-SMO for 12 h, and then cells were exposed to Gli-luc plasmid and Gli1 or Gli2 plasmid transfection for 12 h. After that cell treated with DMSO or 1′-O-methyl-averantin for 48 h. (C,D) Quantitative analysis of mRNA expression levels of Gli1 and SMO on HEK293T cells. HEK293T cells transfected with si-negative control and/or si-SMO for 12 h, and then cells were exposed to Gli1 plasmid and/or mock transfection for 12 h. After that cell treated with DMSO or 1′-O-methyl-averantin for 48 h. 10, 5 and 2.5 µg/ml 1′-O-methyl averantin represent a concentration of 25.90, 12.95 and 6.47 µM, respectively. Data represent the mean ± standard error of the mean, *p < 0.05; **p < 0.01; ***p < 0.001; difference compared with DMSO-treated.